INL 1
Alternative Names: INL-1Latest Information Update: 28 Jan 2023
Price :
$50 *
At a glance
- Originator Innolife
- Class Anti-ischaemics; Cardiovascular therapies; Heart failure therapies
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Heart failure; Ischaemic heart disorders; Myocardial infarction
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Heart-failure in USA (PO, Capsule)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Ischaemic-heart-disorders in China (PO, Capsule)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Myocardial-infarction in China (PO, Capsule)